Yhdysvallat - englanti - NLM (National Library of Medicine)

american health packaging - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 32.4 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

bryant ranch prepack - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 16.2 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

remedyrepack inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 16.2 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

cardinal health - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 16.2 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

mckesson contract packaging - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 15 mg

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - phenobarbital sodium - solution for injection - 200mg/1ml

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

thornton & ross ltd - phenobarbital - oral solution - 3mg/1ml

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - phenobarbital sodium - solution for injection - 60mg/1ml

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - phenobarbital sodium - solution for injection - 30mg/1ml

Yhdysvallat - englanti - NLM (National Library of Medicine)

remedyrepack inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital tablets, usp are indicated for use as a sedative or anticonvulsant. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates. in such patients, severe hepatic damage can occur from ordinary doses and is usually associated with dermatitis and involvement of parenchymatous organs. a personal or familial history of acute intermittent porphyria represents one of the few absolute contraindications to the use of barbiturates. phenobarbital is also contraindicated in patients with marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident. it should not be administered to persons with known previous addiction to the sedative/hypnotic group, since ordinary doses may be ineffectual and may contribute to further addiction. controlled substance: phenobarbital is a schedule iv drug. prolonged, uninterrupted use of barbiturates (particularly the short-acting drugs), even in therapeutic doses, may result in psychic and physical dependence